A Novel Therapeutic Combination for Neuroblastoma The Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor/Rearranged During Transfection Inhibitor Vandetanib With 13-cis-Retinoic Acid

BACKGROUND: High-risk cases of neuroblastoma have poor survival rates, and novel therapies are needed Vandetanib (ZD6474, Zactima) is an inhibitor of the vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases, which have each been implicated in neuroblastoma pathogenesis The authors hypothesized that vandetanib combined with 13-cis-retinoic acid (CRA), a differentiating agent used in most current neuroblastoma treatment regimens, would be effective against neuroblastoma tumor models METHODS: The authors evaluated the effects of vandetanib with and without CRA on RET phosphorylation and on the proliferation and survival of human neuroblastoma cell lines in vitro Using a subcutaneous mouse xenograft model of human neuroblastoma, they analyzed tumors treated with CRA, vandetanib, and the combination of vandetanib plus CPA for growth, gross and histologic appearance. vascularity, and apoptosis RESULTS: Vandetanib treatment inhibited RET phosphorylation and resulted in induction of apoptosis in the majority of neuroblastoma cell lines in vitro, whereas CRA treatment induced morphologic differentiation and cell-cycle arrest Treatment with vandetanib plus CRA resulted in more significant reduction in neuroblastoma cell viability than either alone In a mouse xenograft model, the combination of vandetanib with CPA demonstrated significantly more growth inhibition than either alone, via both reduction in tumor vascularity and induction of apoptosis CONCLUSIONS: Vandetanib induces neuroblastoma tumor cell death in vitro and reduces tumor growth and vascularity in vivo The combination of vandetanib with CPA was more effective in reducing tumor growth than either treatment alone The antitumor effects of vandetanib plus CPA suggest a novel combination for use in neuroblastoma patients Cancer 2010;116:2465-75. (C) 2070 American Cancer Society